Loading...
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri, T Larkin, J Oya, M Martignoni, M Nathan, P Powles, T McDermott, D Robbins, P Chism, D
Choueiri, T
Larkin, J
Oya, M
Martignoni, M
Nathan, P
Powles, T
McDermott, D
Robbins, P
Chism, D
Citations
Altmetric:
Abstract
The combination of an immune checkpoint inhibitor and a VEGF pathway inhibitor to treat patients with advanced renal-cell carcinoma might increase the clinical benefit of these drugs compared with their use alone. Here, we report preliminary results for the combination of avelumab, an IgG1 monoclonal antibody against the programmed cell death protein ligand PD-L1, and axitinib, a VEGF receptor inhibitor approved for second-line treatment of advanced renal-cell carcinoma, in treatment-naive patients with advanced renal-cell carcinoma.
Description
Date
2018-04
Publisher
Collections
Keywords
Type
Article
Citation
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. 2018, 19(4): 451-460 Lancet Oncol